RC
CMMB

RegentAtlantic Capital’s Chemomab Therapeutics CMMB Stock Holding History

RegentAtlantic Capital’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-391
Closed -$43K – 549
2020
Q4 		$43K Hold
391
– – ﹤0.01% 492
2020
Q3 		$29K Hold
391
– – ﹤0.01% 486
2020
Q2 		$34K Buy
+391
New +$26.5K ﹤0.01% 471

Other funds holding CMMB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IF
Ironwood Financial Tucson, Arizona $639M AUM 19.03% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

RegentAtlantic Capital's CMMB Position: Q1 2021 in Review

RegentAtlantic Capital sold out of Chemomab Therapeutics (CMMB) in Q1 2021, closing a stake of 391 shares — an estimated $43K sold.

RegentAtlantic Capital first reported a position in CMMB in Q2 2020 and held it in 3 quarters. The position peaked at $43K in Q4 2020. 10 funds tracked by Wall St. Rank hold CMMB as of Q1 2021.

  • RegentAtlantic Capital reported no remaining Chemomab Therapeutics position as of Q1 2021 after selling out during the quarter.
  • RegentAtlantic Capital sold 391 Chemomab Therapeutics shares in Q1 2021, an estimated $43K.
  • RegentAtlantic Capital first reported a position in Chemomab Therapeutics in Q2 2020 and held it in 3 quarters.
  • RegentAtlantic Capital's Chemomab Therapeutics position peaked at $43K in Q4 2020.
  • 10 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q1 2021.

Based on RegentAtlantic Capital's 13F filing for Q1 2021, filed 29 Apr 2021.